LENZ Therapeutics, Inc.

LENZ Nasdaq SEC CIK 1815776
Follow LENZ Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3.4M −72.9% vs same quarter last year
Net income −$31M −85.4% vs same quarter last year
EPS, diluted −$0.99 −67.8% vs same quarter last year
Operating cash flow −$22.3M −159.8% vs same quarter last year
Revenue by quarter
$0
$0
$5M
$12.5M
$1.6M
$1.9M
$5.5M
$3.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$82.1M
FY24−$49.8M
FY23−$70M
FY22−$101.1M
FY21−$70.8M
FY20−$68.4M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$70M
FY24−$59.9M
FY23−$60.4M
FY22−$94.6M
FY21−$58.6M
FY20−$10.3M
FY19-